Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive， Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer | MicrobiomeTrials
Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive， Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-09-15Est. Completion: 2028-09-15
Enrollment target: 80 participants
Locations
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Estrogen Receptor-Positive Breast CarcinomaHER2-Negative Breast Carcinoma
This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone thera…
Jonesboro, United StatesEst. completion Jul 31, 2029